E-cadherin in gastric cancer

Annie On On Chan

Ann Chan AOO. E-cadherin in gastric cancer. World J Gastroenterol 2006; 12(2):199-203

www.wjgnet.com/1007-9327/12/199.asp

© 2006 The WJG Press. All rights reserved.

Key words: E-cadherin; Gastric cancer

INTRODUCTION

Although decreasing in incidence, gastric cancer remains a major medical problem and is the second most common fatal cancer worldwide. In spite of intense interest and extensive investigations, its prognosis has not been improved significantly in recent years. The dramatic variations in the incidence of gastric cancer in different geographic areas and from one generation to the next have led to the hypothesis that the incidence of gastric cancer is determined largely by environmental rather than genetic factors. The identification and the subsequent classification of Helicobacter pylori (H pylori) infection as type I carcinogen by the WHO sparked a significant understanding in the etiology of gastric cancer. The current discovery of germline mutation at E-cadherin gene in familial gastric cancers and the findings of IL-1 polymorphisms with increased gastric cancer risk again turn the focus towards the studying of host genetics. The molecular studies of the host may give a definite proof of the etiological role of H pylori in inducing gastric carcinoma.

E-CADHERIN

Cadherins are a superfamily of calcium-mediated membrane glycoproteins. E-cadherin is the prototype of the class E-cadherin that links to catenins to form the cytoskeleton. Recent evidence has shown that E-cadherin not only acts as an adhesive, but also plays important roles in growth development and carcinogenesis. It has been recently viewed as an invasion as well as a growth suppressor gene. This review summarizes the recent discoveries on E-cadherin and its role in gastric cancer. In particular, our work on E-cadherin in gastric cancer, including its relation with Helicobacter pylori and clinical applications, are described in detail.

E-CADHERIN AND CANCER

Role of E-cadherin in metastasis

E-cadherin is the prototype of the cadherin class. It is expressed in all epithelial cell types. Underexpression of the E-cadherin is found in gastric and other cancers, and correlates with infiltrative and metastatic ability. It has been proposed that the loss of E-cadherin-mediated cell-cell adhesion is a prerequisite for tumor cell invasion and metastasis formation. Re-establishing the functional cadherin complex, e.g. by forced expression of E-cadherin, results in a reversion from an invasive, mesenchymal, to a benign, epithelial phenotype of cultured tumor cells. Hence, the E-cadherin gene is also called as an invasion...
The expression of E-cadherin has been studied by immunohistochemical method. Decreased expression has been observed in gastric cancer by various authors, ranging from 17%\textsuperscript{[13]} to 92%\textsuperscript{[14]} depending on the method and the definition used. The decreased expression of E-cadherin was mainly observed in diffuse type and less in intestinal type of gastric cancer. Direct correlation between E-cadherin and the grade of tumor differentiation has been observed in all these studies. In addition, it was shown in a study of 413 gastric cancers by Gabbert et al.\textsuperscript{[15]} that patients with E-cadherin positive tumors had significantly better 3- and 5-year survival rates than patients with E-cadherin negative tumors. A similar trend of decrease in disease-free survival was also observed in other cancers exhibiting downregulation of E-cadherin\textsuperscript{[16]}.

We have also studied the change in the expression of the E-cadherin complex along the Correa's cascade in gastric cancer by immunohistochemical staining\textsuperscript{[17]}. We observed that the staining pattern, intensity and the percentage of cells with positive stains deceased along the Correa's cascade; that is, the staining was strong and membranous in normal gastric epithelium, but gradually decreased in intensity and percentage, as well as the pattern was changed towards cytoplasm in chronic atrophic gastritis, intestinal metaplasia, dysplasia and eventually to adenocarcinoma.

However, methods to evaluate, qualitatively or quantitatively, protein expression in biopsies from human tumors may have serious limitations because of sampling from heterogeneous tissue, non-stoichiometric labeling and subjective evaluation.

### MECHANISM OF INACTIVATION OF E-CADHERIN

**Genetic inactivation**

The E-cadherin gene can be genetically inactivated by a number of mechanisms. The first hit of a role for E-cadherin in tumor development, particularly in suppression of invasion, came from loss of heterozygosity studies on chromosome 16. Subsequently, mutations were reported in tumor samples in diffuse type gastric carcinomas\textsuperscript{[18]}. gynecologic cancers\textsuperscript{[19]}\textsuperscript{[20]}, and infiltrative lobular breast cancer\textsuperscript{[21],22].

In gastric cancer, E-cadherin mutations are common in
diffuse type carcinomas, but not seen in intestinal type. The specificity of types of cancer affected by mutations of the E-cadherin gene, despite the prevalence of reduced E-cadherin expression in many cancer types, suggests that E-cadherin mutations may be of particular importance in the development of these tumors. In addition, mutations in diffuse gastric cancer have been detected early in tumor development, suggesting a role in tumor suppression, in addition to invasion suppression. Further evidence for this comes from the observations that mutations of E-cadherin have also been observed in several kindred exhibiting familial gastric cancer. Furthermore, at least one kindred exhibited both diffuse gastric cancer and early-onset breast cancer.

**Inactivation by hypermethylation**
In recent years, it has become increasingly apparent that increased methylation within the promoter regions of genes plays a key role in the inactivation of many important genes during the development of cancer. Subsequently, numerous reports of E-cadherin promoter methylation, associated with reduced E-cadherin expression, have been published. Hypermethylation at E-cadherin has also been shown to play a role in familial gastric cancer, acting as the second hit (the first hit is either mutation or loss of heterozygosity) in inactivation of E-cadherin.

We have previously shown that the immunostaining of E-cadherin decreases along the Correa's cascade; therefore, we went on to study the underlying mechanism. We found that the frequency of methylation at E-cadherin also increases along the Correa's cascade, with the highest frequency detected in the tumorous lesions and metastatic lesions. Methylation frequency correlated with the tumor depth and node invasion. In addition, most of the decrease in immunostaining was accounted for by the presence of methylation at E-cadherin. More importantly, we also observed that *H. pylori* infection was also associated with E-cadherin methylation.

In fact, the role of *H. pylori* in the regulation of E-cadherin has been studied recently. It has been shown that *H. pylori* infection is associated with downregulation of E-cadherin, probably by generating cell signaling events that counteract the normal function of protein kinase C. The resulting increase in permeability mediated by the reduction in cell adhesion might allow *H. pylori* antigens to reach the gastric lamina propria and activate the mucosal immune system, with resultant tissue damage.

In relation to the above findings, we therefore hypothesized that by eradicating *H. pylori*, methylation at E-cadherin may disappear. We performed a prospective randomized trial. Patients with dyspepsia and *H. pylori* infection were randomized to receive *H. pylori* eradication therapy (Group 1, n = 41) or no treatment (Group 2, n = 40) and were followed up prospectively. Gastric mucosae were taken for methylation assay at week 0 (before treatment) and week 6 (after treatment). Methylation was assessed using methylation-specific PCR. Methylation was detected in 46% (19/41) and 17% (7/41) at week 0 and 6, respectively in Group 1 (P = 0.004). 78.9% (15/19) specimens turned unmethylated after eradicating *H. pylori*. Methylation was detected in 47.5% (19/40) and 52.5% (21/40) at weeks 0 and 6, respectively in Group 2 (P = 0.5). Archived specimens with intestinal metaplasia with *H. pylori* infection (n = 22) and without the infection (n = 19) were also retrieved for methylation analysis. But methylation frequency did not differ in *H. pylori* positive or negative intestinal metaplastic specimens (72.7% vs. 63%, P = 0.5). Therefore, we postulated that *H. pylori* eradication therapy could reverse methylation in patients with chronic gastritis only and may halt the process of gastric carcinogenesis.

**Postulated mechanism of helicobacter pylori infection for inducing methylation**
Experimental data from *in vitro* studies support our contention that E-cadherin methylation might be related to *H. pylori* infection. El-Omar et al. reported that interleukin-1β polymorphism that led to upregulation of interleukin-1β with *H. pylori* infection was associated with increased risk of gastric cancer. Furthermore, Hmadcha et al. found that interleukin-1β, through the production of nitric oxide and the subsequent activation of DNA methyltransferase, might induce gene methylation. It is thus possible that *H. pylori* induces methylation through the production of interleukin-1β and hence the downstream activation of nitric oxide and DNA methyltransferase, which subsequently led to an increased risk of E-cadherin methylation and hence gastric cancer.

**OTHER REGULATORY MECHANISMS OF E-CADHERIN**
Loss of E-cadherin function during tumor progression can also be caused by transcriptional repression binding to the CDH1-E box elements, e.g. by the repressors Snail and Sip-1. Tyrosine phosphorylation has also been previously implicated in the regulation of cadherin function: RTKs, such as EGFR, c-Met and FGFR, and the non-receptor tyrosine kinase, c-Src, phosphorylate E-cadherin, CDH1-E box elements, e.g. by the repressors Snail also be caused by transcriptional repression binding to the CDH1-E box elements.

**SOLUBLE E-CADHERIN**
E-cadherin has a cleavage site near the transmembrane domain and artificially produces a soluble 80 ku aminoterminal fragment in the culture medium upon trypsin digestion in the presence of calcium. This soluble E-cadherin fragment is considered to be a degradation product of the 120 ku intact E-cadherin generated by a calcium-dependent proteolytic action, and can be detected in the protein extract of tissue samples from peripheral blood and urine in normal subjects. Serum soluble E-cadherin is reported to be increased in dermatological disorders (bullous pemphigoid, pemphigus vulgaris, psoriasis vulgaris), multi-organ failure, and various tumors like bladder cancer, prostate cancer, lung cancer and gastric cancer. The role of soluble E-cadherin and its biological significance is still, at present, unclear. Recent studies indicate that, in inflammatory condition, serum...
soluble E-cadherin is induced by inflammatory mediators and cytokines\cite{44}; whereas in cancerous diseases, soluble E-cadherin is increased by cleavage of tissue E-cadherin due to overexpressed proteases\cite{48}. The potential of soluble E-cadherin to be a prognostic marker in cancerous diseases has been shown in bladder cancer\cite{23} and gastric cancer\cite{86}.

We have examined the potential clinical application of E-cadherin. We first studied the correlation between E-cadherin immunostaining expression and the concentration in sera\cite{45}. We found that normal strong membranous staining, e.g. in normal gastric epithelium, was associated with low levels of serum soluble E-cadherin, but a partially reduced; cytoplasmic staining, e.g. in intestinal type of gastric cancer, was associated with high levels; whereas complete absence of staining, e.g. in diffuse type of gastric cancer, was associated with low levels of soluble E-cadherin. We also found that soluble E-cadherin may be a potentially useful prognostic marker. High levels of soluble E-cadherin correlated with the depth of tumor invasion, as well as inoperability\cite{46}. More importantly, levels higher than 10,000 ng/mL predicts survival less than 3 years in more than 90% of patients\cite{47}. Currently, we are investigating the use of post-operative soluble E-cadherin levels to predict tumor recurrence in patients who have received curative surgery for gastric cancer.

**CONCLUSION**

Being an adhesion molecule, E-cadherin plays an important role in invasion and metastasis in almost all kinds of epithelial malignancies, and hence is named invasion suppressor gene. However, recent studies have shown that E-cadherin actually plays an early and important role in carcinogenesis and acts as a tumor suppressor gene, particularly in gastric cancer. Further thorough understanding of the role of E-cadherin and its association with extracellular environment and intracellular functions will be extremely important. Potentially, reversing methylation at E-cadherin in the gastric epithelium in patients with H. pylori infection may halt the process of future development of gastric cancer. In addition, soluble E-cadherin may be a useful prognostic marker for gastric cancer.

**REFERENCES**

1. Takeichi M. Morphogenetic roles of classic cadherins. *Curr Opin Cell Biol* 1995; 7: 619-627
2. Yagi T. Takeichi M. Cadherin superfamily genes: functions, genomic organization, and neurologic diversity. *Genes Dev* 2000; 14: 1169-1180
3. Gumbiner BM. Regulation of cadherin adhesive activity. *J Cell Biol* 2000; 148: 399-404
4. Gronwald GB. The structural and functional analysis of cadherin calcium-dependent cell adhesion molecules. *Curr Opin Cell Biol* 1993; 5: 797-805
5. Takeichi M. Cadherins: a molecular family important in selective cell-cell adhesion. *Annu Rev Biochem* 1990; 59: 237-252
6. Takeichi M. Cadherins in cancer: implications for invasion and metastasis. *Curr Opin Cell Biol* 1993; 5: 806-811
7. Birchmeier W, Behrens J. Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. *Biochim Biophys Acta* 1994; 1196: 11-26
8. Vlemmixs K, Vakaet L, Marcel M, Fiers W, van Roy F. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. *Cell* 1991; 66: 107-119
9. Biem M, Clevers H. Linking colorectal cancer to Wnt signaling. *Cell* 2000; 103: 311-320
10. Polakis P. Wnt signaling and cancer. *Genes Dev* 2000; 14: 1837-1851
11. Guilford P, Hopkins J, Harraway J, McLeod M, McLeod N, Harawira P, Taite H, Scoural R, Miller A, Reeve AE. E-cadherin germline mutations in familial gastric cancer. *Nature* 1998; 392: 402-405
12. Gayther SA, Gorringe KL, Ramsay SJ, Huntsman D, Roviello F, Grehan N, Machado JC, Pinto E, Serum A, Halling K, MacLeod P, Powell SM, Jackson CE, Ponder BA, Caldas C. Identification of germ-line E-cadherin mutations in gastric cancer families of European origin. *Cancer Res* 1998; 58: 4086-4089
13. Shimoyama Y, Hirohashi S. Expression of E- and P-cadherin in gastric carcinomas. *Cancer Res* 1991; 51: 2185-2192
14. Mayer B, Johnson JP, Leitl F, Jauch KW, Heiss MM, Schildberg FW, Birchmeier W, Funk I. E-cadherin expression in primary and metastatic gastric cancer: down-regulation correlates with cellular dedifferentiation and glandular disintegration. *Cancer Res* 1993; 53: 1690-1695
15. Gabbert HE, Mueller W, Schneider A, Meier S, Moll R, Birchmeier W, Hommel G. Prognostic value of E-cadherin expression in 413 gastric carcinomas. *Int J Cancer* 1996; 69: 184-189
16. Wijnhoven BP, Dinjens WN, Pignatelli M. E-cadherin-catenin cell-cell adhesion complex and human cancer. *Br J Surg* 2000; 87: 992-1005
17. Chan AO, Wong BC, Lan HY, Loke SL, Chan WK, Hui WM, Yuen YH, Ng I, Hou L, Wong WM, Yuen MF, Luk JM, Lam SK. Deregression of E-cadherin-catenin complex in precancerous lesions of gastric adenocarcinoma. *J Gastroenterol Hepatol* 2003; 18: 534-539
18. Becker KF, Atkinson MJ, Reich U, Becker I, Nekarda H, Siewert JR, Höfler H. E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. *Cancer Res* 1994; 54: 3845-3852
19. Rissing J, Berchuck A, Kohler MF, Boyd J. Mutations of the E-cadherin gene in human gynecologic cancers. *Nat Genet* 1994; 7: 98-102
20. Kanai Y, Oda T, Tsuda H, Ochiai A, Hirohashi S. Point mutation of the E-cadherin gene in invasive lobular carcinoma of the breast. *Jpn J Cancer Res* 1994; 85: 1035-1039
21. Berx G, Cleeton-Jansen AM, Nollet F, de Leeuw WJ, van de Vijver M, Cornelisse C, van Roy F. E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. *EMBO J* 1995; 14: 6107-6115
22. Muta H, Noguchi M, Kanai Y, Ochiai A, Nawata H, Hiroshashi S. E-cadherin gene mutations in signet ring cell carcinoma of the stomach. *Jpn J Cancer Res* 1996; 87: 843-848
23. Costello JE, Plass C. Methylation matters. *J Med Genet* 2001; 38: 285-303
24. Grady WM, Willis J, Guilford PJ, Dunbar AK, Toro TT, Lynch H, Wiesner G, Ferguson K, Eng C, Park JG, Kim SJ, Markowitz S. Identification of germ-line E-cadherin mutations in gastric cancer families of European origin. *Br J Cancer* 1998; 78: 1837-1851
25. Baird AW, Kelleher D. Helicobacter pylori disrupts epithelial cellular dedifferentiation and glandular disintegration. *Cancer Res* 1993; 58: 1690-1695
26. Torrés AM, Pajares JM, O’Toole D, Ahern S, Kelleher D. H pylori infection is associated with downregulation of E-cadherin, a molecule involved in epithelial cell adhesion and proliferation control. *J Clin Pathol* 1998; 51: 410-412
27. Torrés AM, Pajares JM, Hopkins AM, Murphy A, Moran A, Baird AW, Kelleher D. Helicobacter pylori disrupts epithelial barrier function in a process inhibited by protein kinase C activators. *Infect Immun* 1998; 66: 2943-2950
28. Chan AO, Peng JZ, Lam SK, Wong WM, Yuen MF, Cheung HKL, Kwong YL, Rashid A, Hui WM, Wong BCY. Reversal of E-cadherin promoter hypermethylation status after Helicobacter pylori eradication - implication in gastric cancer chemoprevention. *Gastroenterology* 2004; 126(4): Suppl A-38: 333
Identification and purification of a cell surface glycoprotein mediating intercellular adhesion in embryonic and adult tissue. Cell 1983; 34: 455-466

Katayama M, Hirai S, Kamihagi K, Nakagawa K, Yasumoto M, Kato I. Soluble E-cadherin fragments increased in circulation of cancer patients. Br J Cancer 1994; 69: 580-585

Griffiths TR, Brotherick I, Bishop RI, White MD, McKenna DM, Horne CH, Shenton BK, Neal DE, Mellon JK. Cell adhesion molecules in bladder cancer: soluble serum E-cadherin correlates with predictors of recurrence. Br J Cancer 1996; 74: 579-584

Gofuku J, Shiozaki H, Doki Y, Inoue M, Hirao M, Fukuchi N, Monden M. Characterization of soluble E-cadherin as a disease marker in gastric cancer patients. Br J Cancer 1998; 78: 1095-1101

Matsuyoshi N, Tanaka T, Toda K, Okamoto H, Furukawa F, Imamura S. Soluble E-cadherin: a novel cutaneous disease marker. Br J Dermatol 1995; 132: 745-749

Pittard AJ, Banks RE, Galley HF, Webster NR. Soluble E-cadherin concentrations in patients with systemic inflammatory response syndrome and multiorgan dysfunction syndrome. Br J Anaesth 1996; 76: 629-631

Perry I, Tselepis C, Hoyland J, Iqbal TH, Scott D, Sanders SA, Cooper BT, Jankowski JA. Reduced cadherin/catenin complex expression in celiac disease can be reproduced in vitro by cytokine stimulation. Lab Invest 1999; 79: 1489-1499

Noé V, Fingleton B, Jacobs K, Crawford HC, Vermeulen S, Batlle E, Berx G, Vermassen P, Verschueren K, van Grunsven L, Bruyneel E, Mareel M, Huylebroeck D, van Roy F. The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin expression. Mol Cell Biol 2000; 20: 757-766

Chan AO, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, Portillo F, Nieto MA. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2000; 2: 76-83

Comijn J, Berx G, Vermassen P, Verschueren K, van Grunsven L, Bruyneel E, Mareel M, Huyblebroek D, van Roy F. The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol Cell 2001; 7: 1267-1278

Behrens J, Vakaet L, Friis R, Winterhager E, Van Roy F, Mareel MM, Birchmeier W. Loss of epithelial differentiation and gain of invasiveness correlates with tyrosine phosphorylation of the E-cadherin/beta-catenin complex in cells transformed with a temperature-sensitive v-SRC gene. J Cell Biol 1993; 120: 757-766

Hamaguchi M, Matsuyoshi N, Ohnishi Y, Gotot B, Takeichi M, Nagai Y. p60v-src causes tyrosine phosphorylation and inactivation of the N-cadherin-catenin cell adhesion system. EMBO J 1993; 12: 307-314

Fujita Y, Krause G, Scheffner M, Zechner D, Leddy HE, Behrens J, Sommer T, Birchmeier W. Hakai, a c-Cbl-like protein, ubiquitinates and induces endocytosis of the E-cadherin complex. Nat Cell Biol 2002; 4: 222-231

Damsky CH, Richa J, Solter D, Knudsen K, Buck CA. Identification and purification of a cell surface glycoprotein...